cancer-2018-keynote

3 / 8

Page 9
Notes:
allied
academies
July 23-25, 2018 | Moscow, Russia
12th World Cancer Congress
Journal of Medical Oncology and Therapeutics | Volume: 3
Cancer screening biomarkers promise far greater hope to
reduce cancer mortality as compared to cancer treatment
drugs. However, most cancer sites do not have effective
screeningbiomarkers (body fluidor imaging).Why there is sobig
gap between the unmet needs and the potential huge benefit?
The major hurdles are: 1) low incidence of cancer in the
general population, even in high risk population; 2) low
cancer signal at asymptomatic stage; 3) lack of mechanism or
incentive to translate a research assay to a clinical assay; 4)
cost and benefit dilemma (company vs societal); 5) appropriate
roadmap for biomarker development and adoption; 6) rigorous
evaluation of biomarker for its clinical application. Examples
are used to illustrate these challenges and possible solutions.
Conclusions: Multi-disciplinary team with government,
industrial, and academic partnership is required for attacking
this problem. Developing and implementing the road map
guided by a clear clinical goal is necessary for the success.
Speaker Biography
Ziding Feng is a Professor, Kathryn O’Connor Research Professor, and Section Chief of
early detection and biomarkers in the department of Biostatistics, and Co-Director of
the Center for Global Cancer Early Detection at UT MD Anderson Cancer Center. He has
completed his PhD from Cornell University. He has been the principal investigator of the
Data Management and Coordinating Center (DMCC) for the Early Detection Research
Network (EDRN) since 2000, and of the Coordinating and Data Management Center for
the Consortium to Study Chronic Pancreatitis, Diabetes and Pancreatic Cancer (CPDPC)
since 2015. He also has a grant from NCI to incorporate biomarkers to improve lung
cancer risk prediction model using PLCO specimens and data. He is the coordinating
center PI for a study funded by Cancer Prevention Research Institute of Texas (CPRIT)
to establish a large cohort of cirrhosis patients to improve early detection of HCC.
e:
Ziding Feng
The University of Texas MD Anderson Cancer Center, USA
Strategies to improve early detection of Cancer